| Name | Lakeview Village |
|---|---|
| Location | 13840 W 91st Terrace, Lenexa, Kansas |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 158 |
| Occupancy Rate | 60.25% |
| Medicare ID (CCN) | 175242 |
| Legal Business Name | Lakeview Village, Inc. |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1427054048 |
| Organization Name | LAKEVIEW VILLAGE, INC |
| Doing Business As | LAKEVIEW VILLAGE |
| Address | 13840 W 91st Ter, Lenexa, KS 66215 |
| Phone Number | 913-888-1900 |
News Archive
Temasek Life Science Ventures Pte Ltd and Emergent BioSolutions Inc. today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.
Treating mental disorders in children, such as depression, cost $8.9 billion in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality
Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union.
Drexel University College of Medicine researchers are conducting an emergency medicine study to find out the most effective drug for treating established status epilepticus - a life-threatening condition in which the brain is in a state of persistent seizure.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Temasek Life Science Ventures Pte Ltd and Emergent BioSolutions Inc. today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.
Treating mental disorders in children, such as depression, cost $8.9 billion in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality
Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union.
Drexel University College of Medicine researchers are conducting an emergency medicine study to find out the most effective drug for treating established status epilepticus - a life-threatening condition in which the brain is in a state of persistent seizure.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 21.95 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.77 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 67.38 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.79 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 8.65 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.09 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.25 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 5.25 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 99.71 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.18 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 28.97 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 21.69 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.87 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.66 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 50.97 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.44 | 82.93 |
News Archive
Temasek Life Science Ventures Pte Ltd and Emergent BioSolutions Inc. today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.
Treating mental disorders in children, such as depression, cost $8.9 billion in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality
Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union.
Drexel University College of Medicine researchers are conducting an emergency medicine study to find out the most effective drug for treating established status epilepticus - a life-threatening condition in which the brain is in a state of persistent seizure.
› Verified 3 days ago